Medpage Today on MSN15hOpinion
How a Book Is Undermining Progress Against Alzheimer's
Systematic fraud -- led by a "cabal of self-interested researchers, government accomplices, and corporate greed" in the words ...
STAT14h
‘Simply good science’: Women’s health research reveals clues to aging and Alzheimer’s
A special edition of the journal Science focuses on women's health, including links between estrogen and dementia, at a time ...
The Aspen Times10hOpinion
Haims: Prescription antidepressants may have unwanted side effects
The rapid influx of new medications brought to market over the past decade has revolutionized health care by offering new ...
GlobalData on MSN20h
Asceneuron halts Alzheimer’s trial adding to tau-targeting setbacks
After Eli Lilly and Biogen’s setbacks in developing O-GlaNAcase (OGA) inhibitors for Alzheimer’s disease, Asceneuron has now ...
AARP19h
Is It Too Soon to Diagnose Alzheimer’s in People With No Symptoms?
Diagnosing Alzheimer's disease before people have any symptoms is possible, but brings up concerns when so few treatments are ...
Aged Care Insite8h
TGA doubles down on rejection of Alzheimer’s drug
Lecanemab is an antibody infusion therapy, developed by pharmaceutical company Eisai, which has been shown to slow cognitive decline in the early stages of Alzheimer's disease. The drug is ...
Biogen (BIIB) Receives a Hold from Bernstein
In a report released yesterday, William Pickering from Bernstein maintained a Hold rating on Biogen (BIIB – Research Report), with a price ...